Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
91.41
-3.42 (-3.61%)
At close: Mar 5, 2026, 4:00 PM EST
91.41
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:57 PM EST
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Protagonist Therapeutics stock have an average target of 100.17, with a low estimate of 73 and a high estimate of 118. The average target predicts an increase of 9.58% from the current stock price of 91.41.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 6 | 6 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $65 → $95 | Hold | Maintains | $65 → $95 | +3.93% | Mar 3, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $90 → $100 | Strong Buy | Maintains | $90 → $100 | +9.40% | Feb 26, 2026 |
| Barclays | Barclays | Buy Maintains $108 → $113 | Buy | Maintains | $108 → $113 | +23.62% | Feb 26, 2026 |
| Citizens | Citizens | Buy Maintains $102 → $112 | Buy | Maintains | $102 → $112 | +22.52% | Feb 26, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $95 → $118 | Strong Buy | Maintains | $95 → $118 | +29.09% | Feb 2, 2026 |
Financial Forecast
Revenue This Year
373.31M
from 46.02M
Increased by 711.26%
Revenue Next Year
183.86M
from 373.31M
Decreased by -50.75%
EPS This Year
1.89
from -2.05
EPS Next Year
-0.67
from 1.89
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 588.5M | 461.0M | |||
| Avg | 373.3M | 183.9M | |||
| Low | 19.6M | 39.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1,179.0% | 23.5% | |||
| Avg | 711.3% | -50.7% | |||
| Low | -57.4% | -89.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.04 | 2.51 | |||
| Avg | 1.89 | -0.67 | |||
| Low | -2.31 | -2.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 33.2% | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.